Pfizer Inc.
METABOLITES OF GLP1R AGONISTS

Last updated:

Abstract:

The present invention provides metabolites of Compound 1 or a compound of Formula I or III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I or III.

Status:
Application
Type:

Utility

Filling date:

9 Dec 2021

Issue date:

23 Jun 2022